Antitachycardia Pacing for Fast Scar-Mediated Ventricular Tachycardia Across Non-Ischemic Cardiomyopathies: A Case Series.

Int Med Case Rep JSep 11, 2026 (epub)
Case ReportCardiologyOpen access

Paschalis Karakasis, Georgios Stavropoulos, Georgios K Efthimiadis et al.

✦ AI-curated · Sources linked

Case in brief

This case series presents five patients with various non-ischemic cardiomyopathies who experienced fast sustained monomorphic ventricular tachycardia (VT) successfully terminated by antitachycardia pacing (ATP). The patients exhibited distinct arrhythmogenic substrates, including LMNA cardiomyopathy and hypertrophic cardiomyopathy, with episodes reaching rates over 250 beats/min. ATP effectively managed these episodes, highlighting its role in non-shock-dependent VT management.

Diagnostic / clinical pearl

Clinicians should recognize that fast, regular, monomorphic VT in non-ischemic cardiomyopathy may be amenable to termination by ATP, challenging the assumption that such rhythms are always shock-dependent.

Why it matters

Understanding the electrophysiological characteristics of VT can guide device programming and management strategies, potentially reducing unnecessary shocks in patients with non-ischemic cardiomyopathy.

Source

PubMed · PMID 42746419Free full text on PubMed Central

Published in Int Med Case Rep J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.